Orexo AB (OSTO:ORX) LT-Debt-to-Total-Asset : 0.58 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Orexo AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Orexo AB's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.58.

Orexo AB's long-term debt to total assets ratio increased from Dec. 2022 (0.47) to Dec. 2023 (0.58). It may suggest that Orexo AB is progressively becoming more dependent on debt to grow their business.

Orexo AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Orexo AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB LT-Debt-to-Total-Asset Chart

Orexo AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.22

0.04

0.42

0.47

0.58

Orexo AB Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.47	0.54	0.53	0.53	0.58

Orexo AB LT-Debt-to-Total-Asset Calculation

Orexo AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	452.9	/	786.6
	=	0.58

Orexo AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	452.9	/	786.6
	=	0.58

Orexo AB (OSTO:ORX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Orexo AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Orexo AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB (OSTO:ORX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (OSTO:ORX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ORXOY:USA ORXOF:USA 0H19:UK C5G:Germany

Address

Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105

Website

https://www.orexo.com

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments US Pharma, Digital Therapeutics (DTx) and HQ & Pipeline. The majority is from the US Pharma segment. Geographically, the majority is derived from the United States. US Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline include the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB (OSTO:ORX) Headlines

No Headlines